Tag Archives: bmy

Bristol-Myers’ All-Oral HCV Therapy Approved In Japan

Bristol-Myers Squibb won approval in Japan for its all-oral hepatitis C virus (HCV) regimen, an expected but important development for the company as it carves out its place in the crowded HCV market. The stock was down a fraction in midday trading on the stock market today . Bristol-Myers Squibb’s (BMY) therapy is a combination of daclatasvir and asunaprevir , now known by the brand names Daklinza and Sunvepra, respectively. The approval was for

Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

Several key drugs from major drugmakers got endorsements from the European Medicines Agency (EMA) Friday, making commercial approval in the European Union’s enormous market much more likely. Bristol-Myers Squibb’s (BMY) hepatitis C drug daclatasvir, now branded Daklinza, was endorsed by the EMA’s Committee for Medicinal Products for Human Use (CHMP) for use in combination with other hep C drugs, notably Gilead Sciences’ (GILD) Sovaldi. Sovaldi and

Bristol-Myers Stock Up On Nivolumab Trial Success

Bristol-Myers Squibb (BMY) stock was up nearly 3% in early trading on the stock market today, after late Tuesday’s news that the big pharma had stopped a trial of its cancer drug nivolumab early due to strong efficacy. The trial in question compared nivolumab with dacarbazine, a standard chemotherapy also known as DTIC, in previously untreated patients who had advanced melanoma. Bristol’s press release didn’t state exact numbers, but said the